Universität zu Köln

Bucher, Franziska, Parthasarathy, Anand, Bergua, Antonio, Onderka, Jasmine, Regenfuss, Birgit, Cursiefen, Claus and Bock, Felix (2014). Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis. Acta Ophthalmol., 92 (2). S. 143 - 149. HOBOKEN: WILEY. ISSN 1755-3768

Full text not available from this repository.

Abstract

Abstract. Purpose: Ranibizumab (Lucentis((R))) is a Fab-Fragment of a recombinant, humanized, monoclonal VEGF (anti-vascular endothelial growth factor) antibody. This study analyzed the ability of topical Ranibizumab to inhibit lymphangiogenesis in addition to hemangiogenesis after acute corneal inflammation in vivo. In addition, the effect of Ranibizumab on the proliferation of human lymphatic endothelial cells (LECs) and blood endothelial cells (BECs) in vitro was studied. Methods: The inhibitory effect of Ranibizumab on LECs and BECs was studied in vitro using a proliferation enzyme-linked immunosorbent assay (ELISA) assay. To study the in vivo effects of Ranibizumab, the mouse model of suture induced inflammatory corneal neovascularization was used. Study mice received topical Ranibizumab as eye drops. After 1 week excised corneas were stained with LYVE-1 and CD31. Hemangiogenesis and lymphangiogenesis were analyzed morphometrically by using a semiautomatic method based on the image analyzing program Cell^F. Results: An antiproliferative effect of Ranibizumab was seen in vitro on both human BECs and LECs with a significance of p < 0.0001 and p < 0.0004, respectively. In vivo experiments showed that topical application of Ranibizumab significantly inhibits both hemangiogenesis (p = 0.0026) and lymphangiogenesis (p = 0.0026) in the cornea. Conclusion: Ranibizumab is a potent inhibitor of inflammatory corneal hemangiogenesis and lymphangiogenesis in vivo with a direct inhibitory effect on both endothelial cell types in vitro. This study for the first time demonstrates an inhibitory effect of Ranibizumab on lymphatic vessels which could have a wider range of clinical applications.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Bucher, Franziska UNSPECIFIED UNSPECIFIED UNSPECIFIED Parthasarathy, Anand UNSPECIFIED UNSPECIFIED UNSPECIFIED Bergua, Antonio UNSPECIFIED UNSPECIFIED UNSPECIFIED Onderka, Jasmine UNSPECIFIED UNSPECIFIED UNSPECIFIED Regenfuss, Birgit UNSPECIFIED UNSPECIFIED UNSPECIFIED Cursiefen, Claus UNSPECIFIED UNSPECIFIED UNSPECIFIED Bock, Felix UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-444471
DOI:	10.1111/j.1755-3768.2012.02525.x
Journal or Publication Title:	Acta Ophthalmol.
Volume:	92
Number:	2
Page Range:	S. 143 - 149
Date:	2014
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1755-3768
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; SUBCONJUNCTIVAL BEVACIZUMAB; MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB; PHOTODYNAMIC THERAPY; LYMPHATIC VESSELS; SUBGROUP ANALYSIS; VERTEPORFIN PDT; GRAFT-SURVIVAL Multiple languages Ophthalmology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/44447